NCT07469046 2026-03-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
Clinical Trials
21 trialsNCT06483906 2026-03-03
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05906914 2026-02-04
CHA
First Affiliated Hospital of Zhejiang University
Phase 2 Completed
NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT05805072 2023-05-06
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05805098 2023-04-07
VHA
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT05457361 2022-07-14
VAH Versus VA for Salvage Therapy of R/R-AML
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04716114 2021-11-02
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT02440568 2021-07-06
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
University of Illinois at Chicago
Phase 1/2 Terminated
NCT03135054 2020-12-10
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Unknown
NCT03170895 2020-03-30
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Completed
NCT01873495 2019-09-24
Omacetaxine for Consolidation and Maintenance
Emory University
Phase 2 Terminated
NCT04083911 2019-09-10
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT01272245 2018-05-30
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02141477 2018-02-13
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02029417 2016-05-09
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00030355 2013-03-22
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Withdrawn